Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non Hodgkin's lymphomas

S. Monfardini, G. Tancini, M. DeLena, E. Villa, P. Valagussa, G. Bonadonna

Research output: Contribution to journalArticlepeer-review

Abstract

In stage IV non-Hodgkin's lymphomas, CVP (cyclophosphamide, vincristine, and prednisone) was randomly compared to ABP (adriamycin, bleomycin, and prednisone). Of 62 patients entered into the study, 57 (CVP 27, ABP 30) were considered evaluable for comparison. In patients with liver and/or marrow involvement a second biopsy was performed to define complete remission (CR). CR occurred in 48% of patients treated with CVP and in 50% of those given ABP. The median duration of CR was 10.5 and 20.5 mth, respectively. The difference is not statistically significant. Also the survival of complete responders was not significantly different between the 2 treatment groups. After cross-over, secondary treatment with CVP produced an overall response rate of 40% (6 of 15), compared to 50% (6 of 12) obtained with ABP. In the ABP group, 4 patients developed a reversible interstitial pneumonia. In 2 other patients, cardiomyopathy (fatal in one) was observed. In conclusion, although complete remission was similar in both groups, cumulative toxicity occurred in few patients given ABP. However, this combination could represent an effective alternative treatment to be used either in CVP failures or in sequence with CVP.

Original languageEnglish
Pages (from-to)67-74
Number of pages8
JournalMedical and Pediatric Oncology
Volume3
Issue number1
Publication statusPublished - 1977

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non Hodgkin's lymphomas'. Together they form a unique fingerprint.

Cite this